Safety and Effectiveness of Rasagiline in Chinese Patients with Parkinson’s Disease: A Prospective, Multicenter, Non-interventional Post-marketing Study

INTRODUCTION: Rasagiline is indicated for treating idiopathic Parkinson’s disease (PD) as monotherapy and adjunct therapy to levodopa in patients. OBJECTIVES: To assess the post-marketing safety and tolerability of rasagiline in Chinese PD patients, as well as its effectiveness in improving motor sy...

Descripción completa

Detalles Bibliográficos
Autores principales: Su, Wen, Liang, Zhanhua, Mao, Wei, Shao, Ming, Hu, Xingyue, Wu, Yuncheng, Wei, Wenshi, Liu, Zhenguo, Zhang, Kezhong, Tang, Beisha, Cao, Shuai, Song, Zhuolun, Chen, Haibo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2023
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10279558/
https://www.ncbi.nlm.nih.gov/pubmed/37195560
http://dx.doi.org/10.1007/s40264-023-01288-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10279558/
https://www.ncbi.nlm.nih.gov/pubmed/37195560
http://dx.doi.org/10.1007/s40264-023-01288-2

Ejemplares similares